Envista Holdings Corporation

NYSE:NVST Stock Report

Market Cap: US$3.1b

Envista Holdings Valuation

Is NVST undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of NVST when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
US$24.18
Fair Value
24.4% undervalued intrinsic discount
12
Number of Analysts

Below Fair Value: NVST ($18.27) is trading below our estimate of fair value ($26.27)

Significantly Below Fair Value: NVST is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for NVST?

Key metric: As NVST is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for NVST. This is calculated by dividing NVST's market cap by their current revenue.
What is NVST's PS Ratio?
PS Ratio1.2x
SalesUS$2.50b
Market CapUS$3.10b

Price to Sales Ratio vs Peers

How does NVST's PS Ratio compare to its peers?

The above table shows the PS ratio for NVST vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average2.1x
QDEL QuidelOrtho
0.8x2.76%US$2.1b
NVCR NovoCure
3.4x12.01%US$2.1b
LIVN LivaNova
1.8x4.74%US$2.4b
ITGR Integer Holdings
2.4x6.78%US$4.1b
NVST Envista Holdings
1.2x3.05%US$3.1b

Price-To-Sales vs Peers: NVST is good value based on its Price-To-Sales Ratio (1.2x) compared to the peer average (2.1x).

Price to Sales Ratio vs Industry

How does NVST's PS Ratio compare vs other companies in the US Medical Equipment Industry?

56 CompaniesPrice / SalesEstimated GrowthMarket Cap
IART Integra LifeSciences Holdings
0.6x3.97%US$983.84m
EMBC Embecta
0.6x0.79%US$615.40m
OFIX Orthofix Medical
0.5x4.33%US$440.78m
VREX Varex Imaging
0.4x2.58%US$318.40m
NVST 1.2xIndustry Avg. 2.8xNo. of Companies56PS02.85.68.411.214+
56 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: NVST is good value based on its Price-To-Sales Ratio (1.2x) compared to the US Medical Equipment industry average (2.8x).

Price to Sales Ratio vs Fair Ratio

What is NVST's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

NVST PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.2x
Fair PS Ratio1.7x

Price-To-Sales vs Fair Ratio: NVST is good value based on its Price-To-Sales Ratio (1.2x) compared to the estimated Fair Price-To-Sales Ratio (1.7x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst NVST forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$18.27
US$19.04
+4.22%
15.55%US$24.00US$15.00n/a12
May ’26US$16.34
US$19.75
+20.87%
14.63%US$24.00US$15.00n/a12
Apr ’26US$17.10
US$21.33
+24.76%
12.60%US$26.00US$18.00n/a12
Mar ’26US$19.98
US$22.25
+11.36%
10.72%US$26.00US$18.00n/a12
Feb ’26US$20.52
US$21.50
+4.78%
12.52%US$26.00US$17.00n/a12
Jan ’26US$19.29
US$21.33
+10.59%
12.74%US$26.00US$17.00n/a12
Dec ’25US$22.29
US$21.55
-3.34%
13.03%US$26.00US$17.00n/a11
Nov ’25US$20.94
US$21.55
+2.89%
13.03%US$26.00US$17.00n/a11
Oct ’25US$19.34
US$17.90
-7.45%
14.23%US$23.00US$13.00n/a10
Sep ’25US$18.26
US$17.40
-4.71%
10.96%US$20.00US$13.00n/a10
Aug ’25US$16.93
US$18.70
+10.45%
12.21%US$23.00US$16.00n/a10
Jul ’25US$16.11
US$19.77
+22.74%
9.36%US$23.00US$17.00n/a11
Jun ’25US$19.36
US$20.23
+4.48%
10.82%US$24.00US$17.00US$18.2711
May ’25US$19.75
US$23.18
+17.38%
12.72%US$29.00US$18.00US$16.3411
Apr ’25US$20.81
US$24.45
+17.51%
15.73%US$33.00US$19.00US$17.1011
Mar ’25US$20.92
US$24.45
+16.90%
15.73%US$33.00US$19.00US$19.9811
Feb ’25US$23.74
US$28.40
+19.63%
14.10%US$36.00US$22.00US$20.5210
Jan ’25US$24.06
US$29.56
+22.84%
18.19%US$38.00US$22.00US$19.299
Dec ’24US$23.90
US$30.11
+25.99%
16.08%US$38.00US$24.00US$22.299
Nov ’24US$22.99
US$39.89
+73.51%
12.19%US$45.00US$30.00US$20.949
Oct ’24US$27.88
US$42.78
+53.44%
6.31%US$46.00US$38.00US$19.349
Sep ’24US$32.38
US$42.78
+32.11%
6.31%US$46.00US$38.00US$18.269
Aug ’24US$34.01
US$43.22
+27.09%
6.61%US$46.00US$38.00US$16.939
Jul ’24US$33.84
US$44.56
+31.67%
4.11%US$47.00US$41.00US$16.119
Jun ’24US$32.24
US$44.56
+38.20%
4.11%US$47.00US$41.00US$19.369
AnalystConsensusTarget
Consensus Narrative from 12 Analysts
US$19.04
Fair Value
4.1% undervalued intrinsic discount
12
Number of Analysts

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/06/02 04:02
End of Day Share Price 2025/05/30 00:00
Earnings2025/03/28
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Envista Holdings Corporation is covered by 24 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullBaird
Jeffrey JohnsonBaird
Allen LutzBofA Global Research